Cardinal Health, Inc. — Wall Street Analyst Estimates & Price Targets

CAH

NYSEHealthcareMedical - DistributionCIK 0000721371cardinalhealth.comAbout CAH

Last close · Oct 16, 2026254.06+0.35 (+0.14%)

Market cap$58.8B

9 firms' latest targets, last 90 days: median $275.00 ($250.00–$295.00), 8% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 9 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-16	UBS	$295.00	$280.00	▲ 5%	+16%	+16%
2026-08-19	RBC Capital	$276.00	—	—	+17%	+9%
2026-08-13	Barclays	$275.00	$258.00	▲ 7%	+17%	+8%
2026-08-12	Morgan Stanley	$265.00	$255.00	▲ 4%	+12%	+4%
2026-08-12	Evercore ISI	$270.00	$240.00	▲ 13%	+12%	+6%
2026-08-12	Wells Fargo	$277.00	$256.00	▲ 8%	+15%	+9%
2026-08-12	Mizuho Securities	$250.00	$235.00	▲ 6%	+4%	-2%
2026-08-12	Baird	$274.00	$248.00	▲ 10%	+14%	+8%
2026-08-11	Leerink Partners	$292.00	$275.00	▲ 6%	+22%	+15%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2024reported	$226.8B	+11%	$3.45	+245%	est. $224.5B+1%	est. $5.26	9
2025reported	$222.6B	-2%	$6.45	+87%	est. $223.3B+0%	est. $8.20	10
2026reported	$254.2B	+14%	$7.23	+12%	est. $255.9B-1%	est. $10.78	12
2027	$265.8B	+5%	$12.54	+16%	$264.9B–$267.0B	$12.50–$12.59	12
2028	$281.7B	+6%	$14.07	+12%	$275.3B–$289.4B	$13.30–$14.32	12
2029	$297.4B	+6%	$15.59	+11%	$283.1B–$321.0B	$14.25–$17.45	11
2030	$306.5B	+3%	$17.81	+14%	$299.7B–$315.9B	$17.29–$18.52	8
2031	$314.2B	+3%	$20.43	+15%	$307.2B–$323.9B	$19.84–$21.25	8

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$275.00median target, 8% above the last close

Firms with a target · last 90 days: 9
Lowest – highest target: $250.00 – $295.00
Current grades of 11 firms: positive / neutral / negative: 10 / 1 / 0
Upgrades / downgrades · 12 months: 1 / 0
Consensus revenue growth · next 3 FY: +5% a year

Current grades

each firm's latest · 11 firms

As of	Firm	Grade
2026-08-13	TD Cowen	“Buy”
2026-08-13	Barclays	“Overweight”
2026-08-13	J.P. Morgan	“Neutral”
2026-08-12	Wells Fargo	“Overweight”
2026-08-12	Citigroup	“Buy”
2026-08-12	Evercore ISI	“Outperform”
2026-08-12	Mizuho	“Outperform”
2026-08-12	UBS	“Buy”
2026-08-12	Morgan Stanley	“Overweight”
2026-08-12	Baird	“Outperform”
2026-07-02	Bank of America	“Buy”

Grade changes

last 24 months · 7

Date	Firm	Grade
2026-01-09	Citigroup	“Neutral” → “Buy” upgrade
2025-06-03	Wells Fargo	“Equal Weight” → “Overweight” upgrade
2025-02-05	Jefferies	“Hold” → “Buy” upgrade
2025-01-08	TD Cowen	“Hold” → “Buy” upgrade
2025-01-07	Evercore ISI	“In Line” → “Outperform” upgrade
2025-01-06	Bank of America	“Neutral” → “Buy” upgrade
2024-12-13	Wells Fargo	“Underweight” → “Equal Weight” upgrade

46 older than 24 months

2024-02-09	Argus Research	“Hold” → “Buy” upgrade
2023-07-10	Evercore ISI	“Outperform” → “In Line” downgrade
2023-02-03	Baird	“Neutral” → “Outperform” upgrade
2022-11-04	Bank of America	“Underperform” → “Neutral” upgrade
2022-05-26	Barclays	“Overweight” → “Equal Weight” downgrade
2022-05-18	Evercore ISI	“In Line” → “Outperform” upgrade
2022-04-12	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2021-08-06	Deutsche Bank	“Buy” → “Hold” downgrade
2021-08-05	Bank of America	“Buy” → “Underperform” downgrade
2021-05-10	Baird	“Outperform” → “Neutral” downgrade
2020-11-02	Barclays	“Equal Weight” → “Overweight” upgrade
2020-09-25	Deutsche Bank	“Hold” → “Buy” upgrade
2020-05-15	UBS	“Neutral” → “Buy” upgrade
2020-03-20	Bank of America	“Underperform” → “Buy” upgrade
2020-02-12	Morgan Stanley	“Underweight” → “Equal Weight” upgrade
2020-02-07	Baird	“Neutral” → “Outperform” upgrade
2019-12-16	Guggenheim	“Buy” → “Neutral” downgrade
2019-08-27	Argus Research	“Buy” → “Hold” downgrade
2019-08-20	Guggenheim	“Neutral” → “Buy” upgrade
2018-11-16	Leerink Partners	“Outperform” → “Market Perform” downgrade
2018-05-05	Argus	“Hold” → “Buy” upgrade
2018-04-24	Leerink Partners	“Market Perform” → “Outperform” upgrade
2018-04-02	Argus	“Hold” → “Buy” upgrade
2017-11-20	Morgan Stanley	“Equal Weight” → “Underweight” downgrade
2017-11-15	Argus	“Buy” → “Hold” downgrade
2017-09-19	RBC Capital	“Sector Perform” → “Perform” revised
2017-04-19	William Blair	“Outperform” → “Market Perform” downgrade
2017-01-03	Mizuho	“Buy” → “Neutral” downgrade
2016-12-21	Leerink Partners	“Outperform” → “Market Perform” downgrade
2016-10-28	Baird	“Outperform” → “Neutral” downgrade
2016-09-16	Goldman Sachs	“Buy” → “Neutral” downgrade
2016-04-18	Avondale Partners	“Market Outperform” → “Outperform” revised
2016-03-15	TD Cowen	“Outperform” → “Market Perform” downgrade
2016-01-06	Raymond James	“Outperform” → “Market Perform” downgrade
2015-12-17	Goldman Sachs	“Neutral” → “Buy” upgrade
2015-07-14	Evercore ISI	“Buy” → “Hold” downgrade
2015-02-02	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2014-01-08	J.P. Morgan	“Overweight” → “Neutral” downgrade
2013-12-11	Leerink Partners	“Market Perform” → “Outperform” upgrade
2013-11-06	Sterne Agee	“Neutral” → “Buy” upgrade
2013-06-21	William Blair	“Market Perform” → “Outperform” upgrade
2013-03-20	Evercore ISI	“Strong Buy” → “Buy” downgrade
2013-03-20	Citigroup	“Buy” → “Neutral” downgrade
2013-03-19	Lazard	“Buy” → “Neutral” downgrade
2012-10-09	Evercore ISI	“Market Weight” → “Overweight” upgrade
2012-07-12	Evercore ISI	“Market Weight” → “Equal Weight” revised

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.